Camurus AB (publ)

Stockholm Stock Exchange:CAMX.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Sweden

Market Cap

USD 3.53 B

Share Price

USD 60.18

Avg Daily Volume

116,238

Change (1 day)

-0.84%

Change (1 year)

13.25%

Change (YTD)

17.85%

Camurus AB (publ) Net Income Margin for the year ending December 31, 2024: 22.94%

Camurus AB (publ) Net Income Margin is 22.94% for the year ending December 31, 2024, a -8.72% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Camurus AB (publ) Net Income Margin for the year ending December 31, 2023 was 25.13%, a 332.61% change year over year.
Camurus AB (publ) Net Income Margin for the year ending December 31, 2022 was 5.81%, a -138.57% change year over year.
Camurus AB (publ) Net Income Margin for the year ending December 31, 2021 was -15.06%, a -69.75% change year over year.
Camurus AB (publ) Net Income Margin for the year ending December 31, 2020 was -49.78%, a -81.86% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income Margin	EBT Margin	Operating Income Margin	Gross Profit Margin

Stockholm Stock Exchange: CAMX.ST

Camurus AB (publ)

CEO	Mr. Fredrik Tiberg
IPO Date	Dec. 3, 2015
Location	Sweden
Headquarters	Ideon Science Park
Employees	238
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.